Simulations Plus Inc
SLP
Company Profile
Business description
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.
Contact
800 Park Offices Drive
Suite 401
Research Triangle Park
LancasterNC27709
USAT: +1 661 723-7723
Sector
Healthcare
Stock type
Defensive
Industry
Health Information Services
Fiscal Year End
31 August 2026
Employees
213
Stocks News & Analysis
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
We’re expecting another beat-and-raise quarter, while watching the roadmap and discussions of its financing and partnership deals.
stocks
Wide moat airport share steps up its investments
Profits flatten as airport ramps up redevelopment.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,316.70 | 9.20 | 0.10% |
| CAC 40 | 8,453.01 | 31.42 | -0.37% |
| DAX 40 | 26,106.60 | 29.96 | -0.11% |
| Dow JONES (US) | 53,353.52 | 76.51 | 0.14% |
| FTSE 100 | 10,854.32 | 37.76 | 0.35% |
| HKSE | 25,517.33 | 492.13 | -1.89% |
| NASDAQ | 26,050.57 | 129.88 | -0.50% |
| Nikkei 225 | 65,528.09 | 488.27 | -0.74% |
| NZX 50 Index | 13,881.88 | 90.78 | -0.65% |
| S&P 500 | 7,657.78 | 16.59 | -0.22% |
| S&P/ASX 200 | 9,103.10 | 9.90 | 0.11% |
| SSE Composite Index | 3,882.01 | 23.19 | -0.59% |